Abstract

BRUTON’S TYROSINE KINASE NEW EMERGING TREATMENT IN MULTIPLE SCLEROSIS

Jyoshna Ch.*, Bhanu Sanjana K., Dipendru Sahu and Dr. Sd. Abdul Jabbar Basha

.

Abstract

Multiple Sclerosis is a complex autoimmune disease and demyelinating disease [destroying of Myeline Sheath covering] of CNS (Both Brain and Spine). Multiple Sclerosis Produces characteristic lesions which may affect the optic Nerve, Brain, and Spinal cord. It is a Commonest Non-traumatic disability disease to affect young adults. Our review article explains Burton’s tyrosine kinas inhibitor drugs Lymphocytes normal and Cell Sulfate malignant BTK inhibiting are particularly active in Patients with CLL and MCL (Mantle cell lymphoma) chronic lymphocytic leukemia Burton’s tyrosine kinas is a non-receptor kinase that plays a crucial role in oncogenic signaling that is critical for the Proliferation and Survival of leukemic cells in many B cell Malignancies. Bruton's tyrosine kinase inhibiting are particularly active in Patients with CLL (chronic lymphocytic leukemia) and MCL (Mantle cell lymphoma) Bruton's tyrosine kinase gene is located on the X-chromosome gene (xq21.3-q22), At least 400 mutations of the BTK gene have been identified, and at least 212 are considered to be diseases. Causing mutations.

Keywords: .